Teva Seeks To Sell Generic Version Of Bristol HIV Drug
DOW JONES NEWSWIRES
Teva Pharmaceutical Industries Ltd. (TEVA) has filed for U.S. regulatory
approval to sell a generic version of Bristol-Myers Squibb Co.'s (BMY) HIV drug
Reyataz.
Bristol said in a regulatory filing Thursday that Teva filed its application
in October and notified Bristol that it's challenging the validity of two
patents for the drug.
Bristol said it's currently reviewing its legal options. Branded drug makers
often file patent-infringement lawsuits against generics manufacturers that file
for regulatory approval of generic versions of patented drugs. These suits
usually trigger a 30-month stay on regulatory approval of a generic.
Reyataz generated $1 billion in sales for the first nine months of 2009, up 5%
from the year earlier period, Bristol reported Thursday.
-Peter Loftus; Dow Jones Newswires; 215-656-8289; peter.loftus@dowjones.com
(END) Dow Jones Newswires
10-22-091214ET
Copyright (c) 2009 Dow Jones & Company, Inc.
|